Neuropsychological test performance in healthy elderly volunteers before and after donepezil administration: A randomized, controlled study

Leigh J. Beglinger, Oranee Tangphao-Daniels, David A. Kareken, Lu Zhang, Richard Mohs, Eric R. Siemers

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Neuropsychological performance was examined in healthy elderly participants administered the cholinesterase inhibitor donepezil. Of principal interest was examination of the sensitivity of a series of neuropsychological measures to detect cognitive changes after drug administration using typical phase I research parameters (eg, a small sample over a short treatment period). In this double-blind parallel study over a period of 6 weeks, 26 healthy elderly participants (aged 55 to 75 years) were randomized into 1 of 2 arms (14 donepezil and 12 placebo) and completed 14 days of donepezil (5 mg, twice a day) or placebo (twice a day). A battery of neuropsychological tests was administered on days 0, 14 (prerandomization), 28 (end of treatment), and 42 (washout). After 2 weeks of donepezil treatment (day 28), subjects in the donepezil group performed slightly but significantly worse on 2 tests of speed, attention, and short-term memory (P < 0.05) compared with the placebo group. No significant improvement in performance was present on any test during treatment with donepezil. These results are consistent with a previous study in healthy young participants in which transient mild worsening on some cognitive tests during donepezil administration was observed, possibly caused by perturbation of an already optimized cholinergic system in healthy participants. These results are important to consider when designing clinical development plans for putative cognitive-enhancing drugs; in addition, these results raise questions about when the optimal point to begin treatment is for patients who have not yet met criteria for dementia.

Original languageEnglish (US)
Pages (from-to)159-165
Number of pages7
JournalJournal of Clinical Psychopharmacology
Volume25
Issue number2
DOIs
StatePublished - Apr 1 2005

Fingerprint

Neuropsychological Tests
Healthy Volunteers
Placebos
Therapeutics
Cholinesterase Inhibitors
donepezil
Short-Term Memory
Double-Blind Method
Pharmaceutical Preparations
Cholinergic Agents
Dementia
Research

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Neuropsychological test performance in healthy elderly volunteers before and after donepezil administration : A randomized, controlled study. / Beglinger, Leigh J.; Tangphao-Daniels, Oranee; Kareken, David A.; Zhang, Lu; Mohs, Richard; Siemers, Eric R.

In: Journal of Clinical Psychopharmacology, Vol. 25, No. 2, 01.04.2005, p. 159-165.

Research output: Contribution to journalArticle

Beglinger, Leigh J. ; Tangphao-Daniels, Oranee ; Kareken, David A. ; Zhang, Lu ; Mohs, Richard ; Siemers, Eric R. / Neuropsychological test performance in healthy elderly volunteers before and after donepezil administration : A randomized, controlled study. In: Journal of Clinical Psychopharmacology. 2005 ; Vol. 25, No. 2. pp. 159-165.
@article{f9c9f19223424dd8b4a524707ef0982f,
title = "Neuropsychological test performance in healthy elderly volunteers before and after donepezil administration: A randomized, controlled study",
abstract = "Neuropsychological performance was examined in healthy elderly participants administered the cholinesterase inhibitor donepezil. Of principal interest was examination of the sensitivity of a series of neuropsychological measures to detect cognitive changes after drug administration using typical phase I research parameters (eg, a small sample over a short treatment period). In this double-blind parallel study over a period of 6 weeks, 26 healthy elderly participants (aged 55 to 75 years) were randomized into 1 of 2 arms (14 donepezil and 12 placebo) and completed 14 days of donepezil (5 mg, twice a day) or placebo (twice a day). A battery of neuropsychological tests was administered on days 0, 14 (prerandomization), 28 (end of treatment), and 42 (washout). After 2 weeks of donepezil treatment (day 28), subjects in the donepezil group performed slightly but significantly worse on 2 tests of speed, attention, and short-term memory (P < 0.05) compared with the placebo group. No significant improvement in performance was present on any test during treatment with donepezil. These results are consistent with a previous study in healthy young participants in which transient mild worsening on some cognitive tests during donepezil administration was observed, possibly caused by perturbation of an already optimized cholinergic system in healthy participants. These results are important to consider when designing clinical development plans for putative cognitive-enhancing drugs; in addition, these results raise questions about when the optimal point to begin treatment is for patients who have not yet met criteria for dementia.",
author = "Beglinger, {Leigh J.} and Oranee Tangphao-Daniels and Kareken, {David A.} and Lu Zhang and Richard Mohs and Siemers, {Eric R.}",
year = "2005",
month = "4",
day = "1",
doi = "10.1097/01.jcp.0000155822.51962.b4",
language = "English (US)",
volume = "25",
pages = "159--165",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Neuropsychological test performance in healthy elderly volunteers before and after donepezil administration

T2 - A randomized, controlled study

AU - Beglinger, Leigh J.

AU - Tangphao-Daniels, Oranee

AU - Kareken, David A.

AU - Zhang, Lu

AU - Mohs, Richard

AU - Siemers, Eric R.

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Neuropsychological performance was examined in healthy elderly participants administered the cholinesterase inhibitor donepezil. Of principal interest was examination of the sensitivity of a series of neuropsychological measures to detect cognitive changes after drug administration using typical phase I research parameters (eg, a small sample over a short treatment period). In this double-blind parallel study over a period of 6 weeks, 26 healthy elderly participants (aged 55 to 75 years) were randomized into 1 of 2 arms (14 donepezil and 12 placebo) and completed 14 days of donepezil (5 mg, twice a day) or placebo (twice a day). A battery of neuropsychological tests was administered on days 0, 14 (prerandomization), 28 (end of treatment), and 42 (washout). After 2 weeks of donepezil treatment (day 28), subjects in the donepezil group performed slightly but significantly worse on 2 tests of speed, attention, and short-term memory (P < 0.05) compared with the placebo group. No significant improvement in performance was present on any test during treatment with donepezil. These results are consistent with a previous study in healthy young participants in which transient mild worsening on some cognitive tests during donepezil administration was observed, possibly caused by perturbation of an already optimized cholinergic system in healthy participants. These results are important to consider when designing clinical development plans for putative cognitive-enhancing drugs; in addition, these results raise questions about when the optimal point to begin treatment is for patients who have not yet met criteria for dementia.

AB - Neuropsychological performance was examined in healthy elderly participants administered the cholinesterase inhibitor donepezil. Of principal interest was examination of the sensitivity of a series of neuropsychological measures to detect cognitive changes after drug administration using typical phase I research parameters (eg, a small sample over a short treatment period). In this double-blind parallel study over a period of 6 weeks, 26 healthy elderly participants (aged 55 to 75 years) were randomized into 1 of 2 arms (14 donepezil and 12 placebo) and completed 14 days of donepezil (5 mg, twice a day) or placebo (twice a day). A battery of neuropsychological tests was administered on days 0, 14 (prerandomization), 28 (end of treatment), and 42 (washout). After 2 weeks of donepezil treatment (day 28), subjects in the donepezil group performed slightly but significantly worse on 2 tests of speed, attention, and short-term memory (P < 0.05) compared with the placebo group. No significant improvement in performance was present on any test during treatment with donepezil. These results are consistent with a previous study in healthy young participants in which transient mild worsening on some cognitive tests during donepezil administration was observed, possibly caused by perturbation of an already optimized cholinergic system in healthy participants. These results are important to consider when designing clinical development plans for putative cognitive-enhancing drugs; in addition, these results raise questions about when the optimal point to begin treatment is for patients who have not yet met criteria for dementia.

UR - http://www.scopus.com/inward/record.url?scp=15444364185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15444364185&partnerID=8YFLogxK

U2 - 10.1097/01.jcp.0000155822.51962.b4

DO - 10.1097/01.jcp.0000155822.51962.b4

M3 - Article

C2 - 15738747

AN - SCOPUS:15444364185

VL - 25

SP - 159

EP - 165

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 2

ER -